APA (7th ed.) Citation

Kuo, C., Chen, C., Li, C., Huang, G., Ma, W., Hsu, W., . . . Wo, A. M. (2019). Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models. Nature Portfolio.

Chicago Style (17th ed.) Citation

Kuo, Chun-Ting, Chen-Lin Chen, Chih-Chi Li, Guan-Syuan Huang, Wei-Yuan Ma, Wei-Fan Hsu, Ching-Hung Lin, Yen-Shen Lu, and Andrew M. Wo. Immunofluorescence Can Assess the Efficacy of MTOR Pathway Therapeutic Agent Everolimus in Breast Cancer Models. Nature Portfolio, 2019.

MLA (8th ed.) Citation

Kuo, Chun-Ting, et al. Immunofluorescence Can Assess the Efficacy of MTOR Pathway Therapeutic Agent Everolimus in Breast Cancer Models. Nature Portfolio, 2019.